AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05980689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104
Description: During neo-CRT: 2 cycles of AK104, 10mg/kg d1 q3w. After neo-CRT: 3 cycles of AK104, 10mg/kg d1 q3w.
Study NCT05980689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: During neo-CRT: 825mg/m2 bid Monday-Friday per week
Study NCT05980689 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Radiotherapy
Description: IMRT DT: 50Gy/25Fx
Study NCT04962633 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic Pasta
Description: Subjects will consume for 4 weeks 80 g per day of probiotic durum wheat pasta. All subjects will be requested not to change the other daily dietary habits and their physical activity levels during the 4 week intervention period.
Study NCT04962633 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Pasta
Description: Subjects will consume for 4 weeks 80 g per day of conventional durum wheat pasta without probiotics. All subjects will be requested not to change the other daily dietary habits and their physical activity levels during the 4 week intervention period.
Study NCT04862845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine and Pregabalin
Description: will be received pregabalin with duloxetine 90 minutes preoperatively, then pregabalin every 12 hours with duloxetine once daily postoperatively until the fifth postoperative day.
Study NCT04862845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabalin
Description: received pregabalin with a placebo capsule at 90 minutes preoperatively, then every 12 hours postoperatively with a placebo capsule once daily until the fifth postoperative day.
Study NCT04862845 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: sham
Description: received two placebo capsules at 90 minutes preoperatively then placebo capsules every 12 hours, with one capsule daily postoperatively until the fifth postoperative day.
Study NCT06219850 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: The study sample is divided into the six intervention groups of the EDUGUTION study (ClinicalTrials.gov Identifier: NCT05261373), although participants do not receive intervention in the present study, as only a description of the sample is made one year after the EDUGUTION study from a longitudinal perspective.
Study NCT04731168 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mandibular advancement device
Description: Patients will have a mandibular advancement device during the first postoperative night
Study NCT04342039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide Nasal
Description: budesonide 64 mcg/spray; 2 sprays each nostril once daily on days as indicated in the timeline
Study NCT04342039 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 sprays each nostril daily on days as indicated in the timeline
Study NCT04834947 — intervention group
Intervention type: PROCEDURE
Intervention: prone position
Description: Choice of prone positioning a patient is at the discretion of the anesthesia physician.
Study NCT05741515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibular Balance Therapy
Description: see intervention arm description
Study NCT05741515 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Intervention
Description: see sham intervention arm description
Study NCT06422260 — intervention group
Intervention type: OTHER
Intervention: Prosthesis superstructure
Description: Prosthesis superstructure for 2 implant supported short span fixed bride constructed from different materials
Study NCT06014489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: during run-in and extention phase: from Cycle 1 until relapse
Study NCT06014489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: during run-in and extention phase: from Cycle 1 until relapse
Study NCT06014489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat
Description: during run-in phase: from cycle 2 until relapse~during extension phase: from cycle 1 until relapse
Study NCT05485766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg fixed dose, IV, every 3 weeks (Q3W), on Days 1 of Cycles 1-4
Study NCT05485766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m2, IV, weekly, on Days 1, 8, 15 of Cycles 1-4
Study NCT05485766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Area under the curve (AUC 1.5), intravenously (IV), weekly, on Days 1, 8, 15 of Cycles 1-4
Study NCT05485766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 300 mg BID (twice daily) orally
Study NCT05485766 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Definitive Surgery
Description: Each subject will undergo definitive surgery 3-6 weeks after conclusion of the last cycle of the neoadjuvant treatment.
Study NCT04969120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide 10mg
Description: this group receive 10mg intravenous metoclopramide slowly over 2 minutes the medication will be repeated every 2 hours for a maximum three doses
Study NCT04969120 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (0.9 sodium chloride)
Description: this group receive 10mg intravenous placebo(0.9 sodium chloride) slowly over 2 minutes the medication will be repeated every 2 hours for a maximum three doses
Study NCT04588792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulized Furosemide
Description: Furosemide administered by nebulization through the ventilator circuit
Study NCT04588792 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nebulized Saline
Description: Saline administered by nebulization through the ventilator circuit
Study NCT05336955 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intake and quarterly assessment:
Description: The START Plan is designed to evaluate the mental health needs of persons with IDD and measure the capacity of the formal and natural support systems. Family caregivers, or the person primarily responsible for day-to-day care of the person, participate in a formatted interview conducted by START coordinators. The START coordinator completes the initial START Plan during intake and quarterly thereafter. Based on informant responses, an intensity rating is assigned to determine the type, frequency, and duration of services to be provided. Quarterly assessment is conducted to inform development or modification of the Cross-Systems Crisis Prevention and Intervention Plan (D.2.b.2.). Hypothesized causal pathway: Family caregiver engagement in assessment enables the START team to efficiently and effectively identify needs and socially valid solutions that strategically reduce use of emergency services and increase mental health stability.
Study NCT05336955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intake and quarterly assessment:
Description: The START Plan is designed to evaluate the mental health needs of persons with IDD and measure the capacity of the formal and natural support systems. Family caregivers, or the person primarily responsible for day-to-day care of the person, participate in a formatted interview conducted by START coordinators. The START coordinator completes the initial START Plan during intake and quarterly thereafter. Based on informant responses, an intensity rating is assigned to determine the type, frequency, and duration of services to be provided. Quarterly assessment is conducted to inform development or modification of the Cross-Systems Crisis Prevention and Intervention Plan (D.2.b.2.). Hypothesized causal pathway: Family caregiver engagement in assessment enables the START team to efficiently and effectively identify needs and socially valid solutions that strategically reduce use of emergency services and increase mental health stability.
Study NCT05336955 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Consultation & coping skills coaching:
Description: Mental health service consultation is provided by START clinical and medical directors in order to prevent and de-escalate crises. Coping skills coaching, provided by START coordinators, helps to determine with the person, their family, and the system of care how to promote well-being and stability. Successful coping skills for the person are incorporated into the Cross-Systems Crisis Prevention and Intervention Plan. All methods are manualized and reported to meet model fidelity. Hypothesized causal pathway: Providing consultation and coping skills coaching to youth and young adults with IDD, their families, and their system of care increases capacity for crisis prevention and stabilization, reduces emergency service use, and increases quality of care, leading to long-term stability.
Study NCT05336955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consultation & coping skills coaching:
Description: Mental health service consultation is provided by START clinical and medical directors in order to prevent and de-escalate crises. Coping skills coaching, provided by START coordinators, helps to determine with the person, their family, and the system of care how to promote well-being and stability. Successful coping skills for the person are incorporated into the Cross-Systems Crisis Prevention and Intervention Plan. All methods are manualized and reported to meet model fidelity. Hypothesized causal pathway: Providing consultation and coping skills coaching to youth and young adults with IDD, their families, and their system of care increases capacity for crisis prevention and stabilization, reduces emergency service use, and increases quality of care, leading to long-term stability.
Study NCT05336955 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 24-hour urgent crisis response and intervention:
Description: START teams have 24-hour, in-person mobile crisis intervention services. Emergency calls come from a variety of sources; clients, emergency rooms, service providers, families, and law enforcement. START provides immediate telephonic response and in-person evaluation within two hours of the initial contact. Hypothesized causal pathway: Real-time, immediate support enables the successful enactment of crisis evaluation and stabilization. This reduces severity of the crises and allows for diversion from emergency service use.
Study NCT05336955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 24-hour urgent crisis response and intervention:
Description: START teams have 24-hour, in-person mobile crisis intervention services. Emergency calls come from a variety of sources; clients, emergency rooms, service providers, families, and law enforcement. START provides immediate telephonic response and in-person evaluation within two hours of the initial contact. Hypothesized causal pathway: Real-time, immediate support enables the successful enactment of crisis evaluation and stabilization. This reduces severity of the crises and allows for diversion from emergency service use.
Study NCT05336955 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Service linkages, referrals, outreach, & training:
Description: START teams work with stakeholders to develop and maintain linkage agreements. The purpose of these agreements is to enhance the capacity of the system as a whole and develop partnerships to reduce disparities and gaps in the service array. START coordinators conduct crisis prevention-focused outreach visits with the person and/or their system of care. Examples include training during home- and school-based visits, family caregiver coaching to implement new plans or strategies, and checking in with the person to monitor their level of stability. Hypothesized causal pathway: Increased person-centered collaboration and dialogue across systems of care promotes patient perceived quality of care, the identification of more effective strategies that support their mental health needs, and results in reduced use of emergency services.
Study NCT05336955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Service linkages, referrals, outreach, & training:
Description: START teams work with stakeholders to develop and maintain linkage agreements. The purpose of these agreements is to enhance the capacity of the system as a whole and develop partnerships to reduce disparities and gaps in the service array. START coordinators conduct crisis prevention-focused outreach visits with the person and/or their system of care. Examples include training during home- and school-based visits, family caregiver coaching to implement new plans or strategies, and checking in with the person to monitor their level of stability. Hypothesized causal pathway: Increased person-centered collaboration and dialogue across systems of care promotes patient perceived quality of care, the identification of more effective strategies that support their mental health needs, and results in reduced use of emergency services.
Study NCT04892888 — intervention group
Intervention type: BIOLOGICAL
Intervention: COVID-19 Vaccine
Description: COVID-19 Vaccine Intramuscular Injection
Study NCT06027853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLL1 CAR-NK cell injection
Description: Drug: CLL1 NK cell therapy Drug: Cyclophosphamid Lympho-conditioning Agent Drug: Fludarabine Lympho-conditioning Agent~Drug: VP-16 Lympho-conditioning Agent
Study NCT06136923 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CT-100-D-004-A
Description: Attention Biases App CT-100-D-004-A Digital Neuro-activation and Modulation (DiNaMo) component uses implicit training to redirect and strengthen attention processes. This intervention can help improve cognitive capabilities as well as redirect attentional biases to make participants less sensitive to distressing stimuli.
Study NCT06136923 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CT-100-D-004-B
Description: Attention Biases App CT-100-D-004-B Digital Neuro-activation and Modulation (DiNaMo) component uses implicit training to redirect and strengthen attention processes. This intervention can help improve cognitive capabilities as well as redirect attentional biases to make participants less sensitive to distressing stimuli.
Study NCT04678154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Participants in the control group will receive standard of care treatment for their injury, to include all institution specific standard treatment (prophylactic and otherwise) for preventing and treating infection.
Study NCT04678154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin and Tobramycin
Description: The patients in the SEXTANT cohort will have 1000 mg of Vancomycin and 1200 mg of Tobramycin administered to the wound surface, fracture site and exposed hardware (if any) just prior to suture closure of the wound or flap. The SEXTANT cohort will then receive at least 72 hours of systemic antibiotic therapy targeted to the modern wound bioburden.
Study NCT06242314 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: L_PRF
Description: Palatal epithelialization, pain (Visual Analog Scale (VAS) recording), analgesic tablet use and Oral Health Impact Proﬁle-14 (OHIP-14) questionnaire scores were recorded after L-PRF placing on palatal wounds
Study NCT06242314 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: A-PRF
Description: Palatal epithelialization, pain (Visual Analog Scale (VAS) recording), analgesic tablet use and Oral Health Impact Proﬁle-14 (OHIP-14) questionnaire scores were recorded after A-PRF placing on palatal wounds
Study NCT06242314 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Palatal stent
Description: Palatal epithelialization, pain (Visual Analog Scale (VAS) recording), analgesic tablet use and Oral Health Impact Proﬁle-14 (OHIP-14) questionnaire scores were recorded after palatal stent placing on palatal wounds
Study NCT06536803 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: high load strength training and Tissue-specific plantar fascia stretching exercise for 12 weeks
Description: high load strength training and Tissue-specific plantar fascia stretching exercise for 12 weeks
Study NCT06536803 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: high-load strength training with routine physiotherapy
Description: high load strength training with routine physiotherapy for 12 weeks
Study NCT05245760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Tislelizumab
Description: Participants will receive 200mg, every three weeks for up to 51 weeks
Study NCT05245760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Carboplatin (AUC2) and Paclitaxel (50mg/m2), Weekly x 5 weeks
Study NCT05245760 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fractionated radiation
Description: Concurrent with chemo, x5 weeks
Study NCT05245760 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagectomy
Description: Surgical resection of cancer after chemoradiation therapy when no disease progression found.
Study NCT05381467 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: immediate implant placement with The Dual-Zone Therapeutic Concept
Description: After tooth removal, implant placement, bone grafting, and screw retained provisional restoration, the contour of the ridge can change. Using dual zone grafting was claimed to minimize contour change associated with immediate anterior implants. In this technique. The implant should be placed in an optimal 3 dimensional mode . Xenograft, will be used in the gap to graft the bone and tissue zones, . The graft material helps serve as a scaffold to maintain hard- and soft-tissue volume as well as blood clot for initial healing.
Study NCT05381467 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate implant placement with the bone shielding concept
Description: After atraumatic tooth extraction using periotomes and luxators , socket curettage and cleaning simultaneously using an irrigation curette will be performed. Sulcular dissection of the attached tissue close to the socket orifice incisal and apically will be done using periotome to create a tunnel via the socket orifice. Dental implant will be placed. complete access of the labial plate of bone where all the regenerative materials will be performed to have the bone sheild delivered. A membrane will be inserted to the labial tunnel and tacked using 2 membrane tacks.
Study NCT06069960 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sequential adult left lateral lobe liver transplantation (SALT)
Description: Hemihepatectomy combined with left lateral lobe liver transplantation was performed first, and residual liver resection was performed after the graft grew to a sufficient functional liver volume.
Study NCT04743388 — intervention group
Intervention type: BIOLOGICAL
Intervention: BNT162b2
Description: Vaccine against SARS-Cov-2 of the Pfizer/BioNTech companies
Study NCT04743388 — intervention group
Intervention type: BIOLOGICAL
Intervention: Other vaccine against SARS-Cov-2
Description: Any other vaccine authorized and administered by the Greek Ministry of Health against SARS-Cov-2
Study NCT05497856 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated neuromuscular inhibition technique
Description: Ischemic compression will be applied for 90 seconds followed by the SCS technique with a reduction in pain of at least 70%. it will be held for 20-30 sec followed by the Muscle energy technique in which the isometric contraction will be held for 7-10 sec and then the stretch will be held for 30 sec. This will be repeated 5 times per session with a 30-second rest interval in between each repetition Session will be held 3 times per week for 2 consecutive weeks
Study NCT05497856 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Myofascial Release
Description: Deep sustained pressure on the trigger points will be applied with thumb in 5-7/10 pain tolerance and maintained for 60 seconds and then will be released in a vertical direction followed by stretch of the rhomboid muscle held for 30 sec. This Sustained manual pressure will be applied for 3 times each followed by a stretch per session with a 30 sec rest interval in between .Session will be held 3 times per week for 2 consecutive weeks.
Study NCT05834491 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: minimal shoes and foot strengthening and flexibility exercises
Description: Flexible shoes that do not provide support and exercises aimed at increasing the strength of plantar intrinsic and extrinsic foot muscles along with foot flexibility exercises aimed at increasing the range of motion of the foot and ankle
Study NCT05834491 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Footwear, foot orthotic device and foot flexibility exercises
Description: sturdy supportive shoes fitted with supportive foot orthotic devices and foot flexibility exercises aimed at increasing the range of motion of the foot and ankle
Study NCT05154604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1921
Description: Treatment group: Subjects will receive an intravenous infusion of SHR-A1921 in a dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.
Study NCT04808271 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium breve Bif195
Description: 1 capsule daily for 8 weeks
Study NCT04808271 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule daily for 8 weeks
Study NCT05942794 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Screening examination
Description: After an initial clinical visit, all three operators will wear the tissue autofluorescence detection device (GOCCLES®), reporting both observations on their operator-module.
Study NCT06072950 — intervention group
Intervention type: OTHER
Intervention: Usual care
Description: Patients received usual care